In a phase I trial, subthalamic nucleus gene transfer by the AAV-GAD (adeno-associated virus borne glutamic acid decarboxylase) indicated safe, well-tolerated, and significant improvements in motor UPDRS scores in 12 advanced PD patients (Table 2) (NCT00195143) [80]. This evidence concerns the gene GAD1 and Parkinson disease.